[13] Health Science

Technology Policies of MHLW

Overview

Basic Ideas of Technology Study Promotion

Realization of safe and quality healthy life

Promotion of health safety

- Research on health maintenance/promotion of mothers and infants
- Research on lifestyle diseases
- Research on mental health promotion
- Research on prevention, diagnosis, and treatment methods for cancer
- Research on promotion of long-term care prevention
- Research for overcoming immune/allergic diseases
- Research on QOL improvements for disabilities/intractable diseases, etc.

Realization of advanced medical care

- Research on basic technologies for advanced medical care
- Promotion of the development of clinical trial/study foundations
- Promotion of research on practical application of regenerative medicine
- Promotion of research on health, etc.

Security of health safety

- Research on newly emerging/re-emerging infectious diseases, etc.
- Research on health risk management measures
- Research on industrial safety
- Research on medical safety
- Research on harmonization/assessment of regulations on drugs/medical devices, etc.
- Research on food safety, etc.

Promoted in accordance with the Science and Technology Basic Program, etc.

Appropriate Implementation of Human Genome/Genetic Analysis Studies

Overview

Appropriate Implementation of Human Genome/Genetic Analysis Studies

Medical studies involving analysis of the genetic information of humans can be expected to contribute to the identification of the causes of diseases and disease mechanisms, diagnosis/treatment/prevention that reflects the differences in individual physical constitutions (so-called tailor-made treatment), and the development of pharmaceuticals based on genomic information (so-called genomic drug discoveries). However, the genetic information obtained in the course of such a study can reveal the genetic predispositions of the providers and their blood relatives and thus lead to various ethical, legislative, or social problems if inappropriately handled. It is therefore necessary to ensure that any such studies are appropriately implemented with human dignity and human rights fully respected.

In order to promote the appropriate implementation of human genome/genetic analysis studies, therefore, the Ministry of Health, Labour and Welfare (MHLW), the Ministry of Education, Culture, Sports, Science and Technology (MECSST), and the Ministry of Economy, Trade and Industry (METI) jointly formulated and enforced “Ethical Guidelines for Human Genome and Genetic Analysis Research” in April 2001 as guidelines for researchers to observe. In addition, and for the purpose of responding to the smooth implementation of the Act on Protection of Personal Information (Act No. 57 of 2003) and progress made in research, the MHLW in cooperation with MECSST and METI revised the Guidelines in December 2004 from the point of view of protecting personal information by ensuring all the personal information protection measures prescribed for in the said Act. In principle, they were included (MECSST/MHLW/METI Notification No. 1 of 2004). Furthermore, in consideration of the fact that genomic information can now be analyzed faster and easier and genome research styles are becoming more diverse with the recent progress made in human genome/genetic analysis technologies, a revision was also made in February 2013 (MECSST/MHLW/METI Notification No. 1 of 2013). The Guidelines prescribe and request researchers and other relevant parties involved in human genome/genetic analysis studies to observe that informed consent shall be obtained in principle when conducting studies, any institutions involved in studies shall establish an Ethical Review Committee and ensure that the Committee reviews the research plan in advance and approves it, protection of personal information, including genetic information, shall be strictly implemented through on-site inspections by external experts, etc., and consideration shall be given to genetic diseases through implementing genetic consultations, etc.

Appropriate Implementation of Clinical Trials on Gene Therapy

Overview

Appropriate Implementation of Clinical Trials on Gene Therapy

Gene therapy is a new medical technology that administers gene or gene-introduced cells into the human body to treat an illness and can be expected to be an innovative treatment method for serious hereditary diseases, cancer, other terminal diseases, and diseases that severely impair bodily functions. Many clinical trials on gene therapy have already taken place in a number of foreign countries.

For this reason the Ministry of Health, Labour and Welfare (MHLW) formulated “Guidelines for Gene Therapy Clinical Trials” in February 1994, and have been evaluating in a comprehensive manner the medical effectiveness and ethics of gene therapy clinical trials on terminal disease or diseases that severely impair bodily functions via the Committee on Science and Technology of Health Sciences Council. Considering that several years have elapsed since formulation of the Guidelines and that a number of trial cases have been accumulated during this period the Guidelines were revised (Ministry of Education, Culture, Sports, Science and Technology (MECSST)/MHLW Notification No. 1 of 2002) in thereby accelerating evaluation procedures by limiting trial plans that the said Committee evaluates as being of merely novelty value.

The first gene therapy clinical trial in Japan was on adenosine deaminase deficiency, which took place at Hokkaido University. To date 44 applications for clinical trial implementation plans to be evaluated have been made by potential implementing entities, with 40 of them having been determined to be appropriate after being discussed by the Committee on Science and Technology.

In addition, and for the purpose of responding to the smooth implementation of the Act on Protection of Personal Information (Act No. 57 of 2003), MHLW in cooperation with MECSST revised the Guidelines in December 2004 from the point of view of protecting personal information by ensuring all the personal information protection measures prescribed in the said Act. In principle, they were included (MECSST/MHLW Notification No. 2 of 2004). At present, and with the aim of reviewing the Guidelines, an Expert Committee has been established under the Committee on Science and Technology of the Health Sciences Council, and discussions being held.
Appropriate Implementation of Epidemiologic Studies

Overview

Epidemiologic studies investigate the frequency and the distribution of health phenomenon, including the morbidity of diseases, and clarifies the factors associated with it. Epidemiologic studies are considered essential in investigating the causes of diseases, verifying the effectiveness of prevention/treatment methods used with diseases, or clarifying the relationship between environment/life styles and health, and thus play a significant role in the progress of medicine and the maintenance and improvement of public health. In recent years, however, providing research subjects with explanations and obtaining their agreement has been considered important. Furthermore, an increased awareness on the rights to privacy and social trends in private information protection has necessitated clarification of legally binding standards.

Because of the above reasons the Ministry of Health, Labour and Welfare (MHLW), in cooperation with the Ministry of Education, Culture, Sports, Science and Technology (MECSST), formulated “Ethical Guidelines for Epidemiologic Studies” (MECSST/MHLW Notification No. 2 of 2002) in June 2002. The Guidelines prescribe that, when conducting epidemiologic studies, informed consent shall be obtained from the research subjects, in principle, study plans reviewed by an Ethical Review Committee established at the pertinent research institute, and a personal information protection system established, etc., while also requiring researchers, etc. engaged in epidemiologic studies to observe the promotion of the appropriate implementation of epidemiologic studies.

In addition, and for the purpose of responding to the smooth implementation of the Act on Protection of Personal Information (Act No. 57 of 2003), the MHLW, in cooperation with MECSST, revised the Guidelines in December 2004 from the point of view of protecting personal information by ensuring all personal information protection measures prescribed in the said Act, in principle, were included (MECSST/MHLW Notification No. 1 of 2004).

Furthermore, provisions regarding the obligations of the directors of research institutions and protection of research subjects, etc. were established in August 2009 (MECSST/MHLW Notification No. 1 of 2009).

Appropriate Implementation of Clinical Trials

Overview

Clinical trials are conducted on humans for the purpose of preventing diseases, improving diagnostic/treatment methods, improving understanding of the causes and pathologies of diseases, and improving the quality of life of patients. With the progress being made in science and technology in recent years their importance is further increasing.

In addition, medical advances will ultimately and inevitably depend on clinical trials, and therefore appropriate implementation of clinical trials needs to be promoted through obtaining social understanding and cooperation and with human dignity and human rights fully respected.

Because of the above reasons the Ministry of Health, Labour and Welfare (MHLW) formulated the “Ethical Guidelines for Clinical Trials” (MHLW Notification No. 255 in 2003) in July 2003, which cover all clinical trials, in thus promoting their appropriate implementation. The Guidelines prescribe that, when conducting clinical trials, sufficient explanations shall be provided to the research subjects before obtaining their consent, consideration be given to the protection of the personal information of the research subjects, and the appropriateness and consistency of any clinical trials reviewed by an Ethical Review Committee established at the pertinent research institute, etc. In addition, the Guidelines were revised in December 2004 to include the necessary provisions to ensure the appropriate handling of personal information in clinical trials. Furthermore, an overall review of the Guidelines took place in July 2008 in further improving research ethics and protecting the research subjects. All relevant parties involved in clinical trials are requested to observe the said Guidelines in thus promoting the appropriate implementation of clinical trials.

An Expert Committee was established under the Committee on Sciences Council in December 2012 to discuss revisions of both the said Guidelines and the “Ethical Guidelines for Epidemiologic Studies” in a unified manner. “Ethical Guidelines for Medical Research on Humans” that integrated both Guidelines was compiled at a joint session between the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare in May 2014.

Appropriate Implementation of Clinical Trials involving Human Stem Cells

Overview

Clinical trials on human stem cells play an important role in maintaining public health and preventing, diagnosing, and treating diseases through organ function regeneration, etc.

Because of the above reasons the Ministry of Health, Labour and Welfare (MHLW) formulated “Guidelines for Clinical Trials using Human Stem Cells” (MHLW Notification No. 425 in 2006) in July 2006 in thereby ensuring that all clinical trials involving human stem cells are appropriately implemented/promoted through obtaining the understanding of society and get implemented with human dignity and human rights fully respected, and effectiveness and safety secured based on scientific knowledge.

Since enforcement of the Guidelines, anyone engaging in clinical trials involving human stem cells has been requested to observe the aforementioned guidelines. However, revisions have been made to the relevant laws and ordinances, as well as new stem cell technologies developed, which include human embryonic stem cells (human ES cells) and human-induced pluripotent stem cells (human iPS cells), etc., with progress also having been made in basic research, etc. In order to respond to these changes in environment surrounding clinical studies on human stem cells, discussion on reviewing the Guidelines took place at “Expert Committee on Reviewing the Guidelines for Clinical Trials using Human Stem Cells”, Human ES cells and human iPS cells, etc. were newly covered by the Guidelines in addition to somatic stem cells in November 2010 (2010 revision), and some clinical trials using human ES cells were allowed in October 2013 (2013 revision). In addition, “Expert Committee on Securing Safety and Promotion of Regenerative Medicine” was established in September 2012 to discuss a system to promote practical application of regenerative medicine provided as medical care while securing sufficient safety, etc., and the “Draft Act on the Safety of Regenerative Medicine” based on the report of the said Expert Committee was submitted to the Diet in May 2013. The “Act on the Safety of Regenerative Medicine” (Act No. 85 of 2013) was established in November of the same year. Since that the said Act applies to clinical trials covered by the conventional Guidelines, the Guidelines for Clinical Trials using Human Stem Cells is scheduled to be abolished when the said Act is enforced in November 2014.